A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome

Table 5 Randomized control trials of treatments for ARDS published after 1998

Author	Derdak⁴⁰	Eisner⁴¹	Gattinoni⁴²	ARDS network⁴³	Ely⁴⁴	Lagneau⁴⁵
Subjects	All comers ARDS	Pneumonia ARDS	All comers ARDS	All comers ARDS	ARDS network (age <70)	Pa02/FiO2 < 200
Intervention	Ventilation-controlled or high frequency	Tidal volume 12 ml/kg or 6 ml/kg	Supine vs. prone	Placebo vs. ketoconazole	Tidal volume 12 ml/kg or 6 ml/kg	Cisatracurium 0/4 twitches or 2/4 twitches
# of subjects	147	320	304	234	729	102
Mean age (yrs)	49	51	58	53	46	56
Severity of illness	22**	84***	40*	81***	73***	41*
Pa02/FiO2	113	133	127	145		130
ICU days					19
Days on ventilator	21				10
In-hospital mortality				35%		45%
% with unassisted breathing at 1 mth		57%		59%
10 day mortality			25%, 21%
30 day mortality	52%, 37%				25%
6 mth mortality	59%, 47%	36%	59%, 63%		30%
Ventilator free days in first 28 days				10
reintubation					7.5%